Complementary, alternative medicine integration into clinical cancer care needs to be individualized
the ONA take:
Researchers at the Abramson Cancer Center at the University of Pennsylvania’s Perelman School of Medicine conducted a survey-based study to determine what drives the use of complementary and alternative medicine (CAM) among cancer patients.
The researchers surveyed 969 patients from the institution’s thoracic, breast, and gastrointestinal medical oncology clinics.
The findings reveal that expectation of therapeutic benefits, patient-perceived barriers regarding cost and access, and opinions of patients’ physician and family members predict patients’ use of CAM.
These beliefs and attitudes varied by key socio-demographic factors such as sex, race, and education.
Proven effectiveness of CAM practices such as yoga and acupuncture continue to support the practice of integrative oncology, which merges complementary and alternative medicine with conventional medicine to improve patient outsomes.
The researchers conclude that patient education on CAM practices should be tailored to the individual patient when integrating them into clinical care.
A study to determine what drives the use of complementary and alternative medicine among cancer patients.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|